The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors Corrigendum in /10.3892/ijo.2019.4874

Nestal de Moraes,Gabriela; Castro,Carolina  Pereira; Salustiano,Eduardo  Jesus; Dumas,Matheus  Lourenço; Costas,Fernanda; Lam,Eric  Wing-Fai; Costa,Paulo  Roberto Ribeiro; Maia,Raquel  Ciuvalschi

doi:10.3892/ijo.2014.2615

The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors

Corrigendum in: /10.3892/ijo.2019.4874

Authors:
- Gabriela Nestal de Moraes
- Carolina Pereira Castro
- Eduardo Jesus Salustiano
- Matheus Lourenço Dumas
- Fernanda Costas
- Eric Wing-Fai Lam
- Paulo Roberto Ribeiro Costa
- Raquel Ciuvalschi Maia
View Affiliations

Affiliations: Laboratory of Cellular and Molecular Hemato-Oncology, Program of Molecular Hemato-Oncology, Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil, Laboratory of Bioorganic Chemistry, Research Nucleous of Natural Products, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil, Laboratory of Tumor Immunology, Leopoldo de Meis Medical Biochemistry Institute (IBqM-UFRJ), Rio de Janeiro, RJ, Brazil, Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK
Published online on: August 21, 2014 https://doi.org/10.3892/ijo.2014.2615
Pages: 1949-1958

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) patients' outcome is usually poor, mainly because of drug resistance phenotype. The identification of new drugs able to overcome mechanisms of chemoresistance is essential. The pterocarpanquinone LQB-118 compound has been shown to have a potent cytotoxic activity in myeloid leukemia cell lines and patient cells. Our aim was to investigate if LQB-118 is able to target FoxO3a and FoxM1 signaling pathways while sensitizing AML cell lines. LQB-118 induced apoptosis in both AML cell lines HL60 (M3 FAB subtype) and U937 (M4/M5 FAB subtype). Cell death occurred independently of alterations in cell cycle distribution. In vivo administration revealed that LQB-118 was not cytotoxic to normal bone marrow-derived cells isolated from mice. LQB-118 induced FoxO3a nuclear translocation and upregulation of its direct transcriptional target Bim, in HL60 cells. However, LQB-118 induced FoxO3a nuclear exclusion, followed by Bim downregulation, in U937 cells. Concomitantly, LQB-118 exposure reduced FoxM1 and Survivin expression in U937 cells, but this effect was more subtle in HL60 cells. Taken together, our data suggest that LQB-118 has a selective and potent antitumor activity against AML cells with distinct molecular subtypes, and it involves differential modulation of the signaling pathways associated with FoxO3a and FoxM1 transcription factors.

View Figures

View References

1	Kumar CC: Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2:95–107. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar
3	Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–3849. 1999.
4	O’Donnell MR, Abboud CN, Altman J, et al: Acute myeloid leukemia. J Natl Compr Cancer Netw. 10:984–1021. 2012.
5	Tallman MS, Nabhan C, Feusner JH, et al: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 99:759–767. 2002. View Article : Google Scholar : PubMed/NCBI
6	Smith ML, Hills RK and Grimwade D: Independent prognostic variables in acute myeloid leukaemia. Blood Rev. 25:39–51. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wood WA and Lee SJ: Malignant hematologic diseases in adolescents and young adults. Blood. 117:5803–5815. 2011. View Article : Google Scholar : PubMed/NCBI
8	Shaffer BC, Gillet JP, Patel C, et al: Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
9	Netto CD, Santos ES, Castro CP, et al: (+/−)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives: cytotoxic effect on human leukemia cell lines. Eur J Med Chem. 44:920–925. 2009.
10	Netto CD, da Silva AJ, Salustiano EJ, et al: New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells. Bioorg Med Chem. 18:1610–1616. 2010. View Article : Google Scholar : PubMed/NCBI
11	Maia RC, Vasconcelos FC, de Sá Bacelar T, et al: LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs. 29:1143–1155. 2011.
12	Salustiano EJ, Netto CD, Fernandes RF, et al: Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells. Invest New Drugs. 28:139–144. 2010. View Article : Google Scholar : PubMed/NCBI
13	de Sá Bacelar T, da Silva AJ, Costa PR, et al: The pterocarpanquinone LQB 118 induces apoptosis in tumor cells through the intrinsic pathway and the endoplasmic reticulum stress pathway. Anticancer Drugs. 24:73–83. 2013.PubMed/NCBI
14	Adida C, Recher C, Raffoux E, et al: Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 111:196–203. 2000. View Article : Google Scholar : PubMed/NCBI
15	Tamm I, Kornblau SM, Segall H, et al: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 6:1796–1803. 2000.PubMed/NCBI
16	Wuchter C, Leonid K, Ruppert V, et al: Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Leukemia. 14:1018–1024. 2000.
17	Nestal de Moraes G, Silva KL, Vasconcelos FC, et al: Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncol Rep. 25:1613–1619. 2011.PubMed/NCBI
18	Nestal de Moraes G, Souza PS, Costas FC, et al: The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leuk Res Treatment. 2012:6717022012.PubMed/NCBI
19	Silva KL, de Souza PS, Nestal de Moraes G, et al: XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res. 37:1350–1358. 2013. View Article : Google Scholar : PubMed/NCBI
20	Souza PS, Vasconcelos FC, De Souza Reis FR, et al: P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol. 39:925–933. 2011.
21	de Souza Reis FR, de Faria FC, Castro CP, et al: The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells. Anticancer Agents Med Chem. 13:341–351. 2013.PubMed/NCBI
22	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chapuis N, Park S, Leotoing L, et al: IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FoxO3a activity in acute myeloid leukemia. Blood. 116:4240–4250. 2010.
24	Yang JY and Hung MC: A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zhang X, Tang N, Hadden TJ, et al: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
26	Leung TW, Lin SS, Tsang AC, et al: Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 507:59–66. 2001. View Article : Google Scholar : PubMed/NCBI
27	Wang IC, Chen YJ and Hughes D: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
28	Nakamura S, Hirano I, Okinaka K, et al: The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wilson MS, Brosens JJ, Schwenen HD, et al: FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets. 12:1256–1266. 2011. View Article : Google Scholar : PubMed/NCBI
30	Gallagher R, Collins S, Trujillo J, et al: Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 54:713–733. 1979.PubMed/NCBI
31	Lee KH, Chang MY, Ahn JI, et al: Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. Biochem Biophys Res Commun. 296:1125–1133. 2002. View Article : Google Scholar : PubMed/NCBI
32	Ralph P, Harris PE, Punjabi CJ, et al: Lymphokine inducing ‘terminal differentiation’ of the human monoblast leukemia line U937: a role for gamma interferon. Blood. 62:1169–1175. 1983.
33	Cáceres-Cortés JR: Blastic leukaemias (AML): a biologist’s view. Cell Biochem Biophys. 66:13–22. 2013.PubMed/NCBI
34	Lorin S, Hamaï A, Mehrpour M, et al: Autophagy regulation and its role in cancer. Semin Cancer Biol. 23:361–379. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wrighton KH: Autophagy: kinase crosstalk through beclin 1. Nat Rev Mol Cell Biol. 14:402–403. 2013. View Article : Google Scholar : PubMed/NCBI
36	Sunters A, Fernández de Mattos S, Stahl M, et al: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI
37	Kelly RJ, Lopez-Chavez A, Citrin D, et al: Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med. 11:633–649. 2011. View Article : Google Scholar
38	Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site. 2013
39	da Cunha EF Júnior, Pacienza-Lima W, Ribeiro GA, et al: Effectiveness of the local or oral delivery of the novel naphthop-terocarpanquinone LQB-118 against cutaneous leishmaniasis. J Antimicrob Chemother. 66:1555–1559. 2011.
40	Ribeiro GA, Cunha-Júnior EF, Pinheiro RO, et al: LQB-118, an orally active pterocarpanquinone, induces selective oxidative stress and apoptosis in Leishmania amazonensis. J Antimicrob Chemother. 68:789–799. 2013. View Article : Google Scholar : PubMed/NCBI
41	Van Der Heide LP, Hoekman MF and Smidt MP: The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 380:297–309. 2004.PubMed/NCBI
42	Santamaría CM, Chillón MC, García-Sanz R, et al: High FoxO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res. 33:1706–1709. 2009.PubMed/NCBI
43	Sykes SM, Lane SW, Bullinger L, et al: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemia. Cell. 146:697–708. 2011. View Article : Google Scholar : PubMed/NCBI
44	Kornblau SM, Singh N, Qiu Y, et al: Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res. 16:1865–1874. 2010. View Article : Google Scholar
45	Sakoe Y, Sakoe K, Kirito K, et al: FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acutepromyelocytic leukemia. Blood. 115:3787–3795. 2010. View Article : Google Scholar : PubMed/NCBI
46	Thépot S, Lainey E, Cluzeau T, et al: Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 10:2323–2330. 2011.PubMed/NCBI
47	Kelly KR, Nawrocki ST, Espitia CM, et al: Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 131:2693–2703. 2012. View Article : Google Scholar
48	Scheijen B, Ngo HT, Kang H, et al: FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene. 23:3338–3349. 2004. View Article : Google Scholar : PubMed/NCBI
49	Zhao F and Lam EW: Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med. 6:376–380. 2012. View Article : Google Scholar : PubMed/NCBI
50	Koo CY, Muir KW and Lam EW: FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
51	Zhang X, Zeng J, Zhou M, et al: The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI